Statin-associated autoimmune myopathy: Current perspectives

Research output: Contribution to journalReview articlepeer-review

Abstract

Although generally well tolerated, statin users frequently report muscle-related side effects, ranging from self-limiting myalgias to rhabdomyolysis or the rare clinical entity of statin-associated immune-mediated necrotizing myopathy (IMNM). Statin-associated IMNM is based on the development of autoantibodies against 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol synthesis and the pharmacologic target of statins, and leads to a necrotizing myopathy requiring immunosuppressive therapy. This review attempts to recapitulate the diverse aspects of anti-HMGCR IMNM, including clinical presenta-tion, diagnostic modalities, genetic risk associations, therapeutic options and potential pathoge-netic pathways.

Original languageEnglish (US)
Pages (from-to)483-492
Number of pages10
JournalTherapeutics and Clinical Risk Management
Volume16
DOIs
StatePublished - 2020

Keywords

  • Anti-HMGCR
  • Myopathy
  • Stains
  • Statin myopathy
  • Statin toxicity

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Fingerprint Dive into the research topics of 'Statin-associated autoimmune myopathy: Current perspectives'. Together they form a unique fingerprint.

Cite this